Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O9XO
|
|||
| Former ID |
DIB003312
|
|||
| Drug Name |
KH-902
|
|||
| Synonyms |
Fumintide; KH-902 (intravitreal, AMD/DME), Kanghong Biotechnologies
Click to Show/Hide
|
|||
| Indication | Diabetic macular edema [ICD-11: 9B71.02] | Phase 3 | [1] | |
| Company |
Chengdu Kanghong Biotechnologies Co Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor receptor (VEGFR) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01436864) A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD. U.S. National Institutes of Health. | |||
| REF 2 | Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.